Correction: Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study


The article has been corrected since it was published online.

In the Results section of the abstract (page 1), sentence 4 should read “Radiographic non-progression rates (change in vdH-mTSS≤smallest detectable change (1.9)) were 88.1% and 75.4% in abatacept and placebo groups, respectively.”

In the “Radiographic assessment” paragraph of the Methods section (page 2), sentence three should read “The rate of radiographic non-progression at week 24, defined as the proportion of patients with a change from baseline vdH-mTSS ≤1.9 (smallest detectable change (SDC)), was a secondary endpoint.”

In the “Radiographic assessment” section of the Results (page 7, paragraph 2), sentence two should read “The radiographic non-progressor rates in the abatacept plus MTX group and the placebo plus MTX group were evaluated by the proportion of patients with change from baseline in vdH-mTSS below SDC (1.9), 0.5 or 0 at week 24 and week 52 (see online supplementary table S1).”

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

RMD Open 2019;5:e000813corr1. doi:10.1136/rmdopen-2018-000813corr1